RxDoctor Payments Data

Jordan Kawano, MD

Cardiovascular Disease · Santa Monica, CANPI 1225353592

Payments from drug & device makers

$77,044in general payments, 2019–2025

Across 225 payments — averaging $342.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$74K
  • Novartis$1K
  • Johnson & Johnson$386
  • Amgen$341
  • E.r. Squibb & Sons, L.L.C.$253
  • Pfizer$244
  • plus $826 from 23 others

What the payments were for

  • Food & beverage$3,944100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$77,044 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$469,807
Medicare patients
1,181
Services billed
12,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban188$201,957
Repatha SureclickEvolocumab183$187,407
EntrestoSacubitril/Valsartan129$133,616
Repatha SyringeEvolocumab61$75,558
OzempicSemaglutide38$40,286
WegovySemaglutide25$40,284
Praluent PenAlirocumab36$32,785
JardianceEmpagliflozin28$31,536
XareltoRivaroxaban16$17,623
BrilintaTicagrelor18$12,598
LivaloPitavastatin Calcium13$10,593
FarxigaDapagliflozin Propanediol13$8,425
Rosuvastatin Calcium481$8,119
Ezetimibe150$5,982
Atorvastatin Calcium467$5,899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$244$201,957188 claims
NovartisEntresto$1,420$133,616129 claims
Novo NordiskOzempic, Wegovy$94$80,56963 claims
Boehringer IngelheimJardiance$47$31,53628 claims
AstraZenecaBrilinta, Farxiga$40$21,02331 claims
Johnson & JohnsonXarelto$386$17,62316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →